News Agency
The Times

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

  • Written by PR Newswire
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in...

Read more: PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2...

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion